Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea
Wiese, B. M.; Bondarenko, E.; Feldman, J. L.
Show abstract
Using a mouse equivalent of FDA-approved cannabidiol (CBD) dosing, we found high dose CBD affects opioid induced persistent apnea (OIPA), the principal cause of opioid related fatalities. CBD pretreatment mitigated respiratory depression from fentanyl in awake mice and significantly delayed OIPA onset in anesthetized mice, effective as the opioid antagonist naloxone. The powerful effect of CBD pretreatment on OIPA suggests a novel therapeutic strategy to reduce fatal opioid overdose incidence.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impaired trigeminal control of ingestive behavior in the Prrxl1- / - mouse is associated with a lemniscal-biased orosensory deafferentation 91%
- Differences in sensory nerve block between levobupivacaine and bupivacaine at low concentrations in humans and animals 90%
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons 90%
Similar papers in this journal
Similar papers in this journal
- Protectin DX resolves fracture-induced postoperative pain in mice via neuronal signaling and GPR37-activated macrophage efferocytosis 88%
- Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice 88%
- Rescue of alveolar wall liquid secretion blocks fatal lung injury by influenza-staphylococcal coinfection 87%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.